segunda-feira, 12 de setembro de 2011

The hidden target - a new cancer immunotherapy?

In the last issue of Science Translational Medicine, a team from the National University of Singapore report the intriguing finding that intracellular tumor antigen–specific monoclonal antibodies could inhibit tumor growth and metastasis and prolong survival of tumor-bearing mice. As this is a dogma-challenging discovery, a lot of questions naturally arise. Just how the antibodies directed to intracellular proteins managed to effect cell toxicity? Are these results possibly reproducible in humans? Could this be a whole new monoclonal antibody-based strategy for cancer treatment? Antibody-based therapies are targeted at specific molecular elements of cells (often receptor proteins) and thus have improved safety over standard chemotherapy regimens, which has resulted in extended survival and improved quality of life for cancer patients with conventional treatment refractoriness. Because antibodies are too large to cross intact cell membrane and access intracellular locations, antibody therapy has traditionally targeted extracellular or secreted proteins expressed by cancer cells. However, many oncogenic proteins are found within the cell (such as intracellular phosphatases/kinases and transcription factors) and have therefore not been targets for usual antibody therapies. In their proof-of-concept experiment, researchers have treated animals with antibodies directed at intracellular proteins or with endogenous antibody formation by vaccination with these protein products. As a result, they obtained in vitro and in vivo tumor growth inhibition with this strategy. Theoretical possibilities to explain these unexpected effects could be: (1) a small fraction of intracellular antigens may be released due to necrosis or cancer cell lysis; (2) some intracellular antigens may be externalized and displayed on the surface of cancer cells by unconventional secretion; (3) binding of antibodies to surface-exposed intracellular proteins may then trigger immune responses such as ADCC to destroy the cancer cells; (4) antibodies could be taken up by the cancer cells in an antigen-specific manner; (5) complement-mediated events may also be involved. Truly, this effect remains a mistery to be explained, but with plenty of promise if could be confirmed and translated to human patients.
Read the complete article: http://bit.ly/nT1HbL

Clique aqui!

2015 A.C. Camargo academic journals acesso aberto adverse drug reactions alergia alquilantes alto custo ambiente ambientes virtuais analgésicos anomalias vasculares anti-eméticos anti-helmínticos anti-histamínico antianêmicos antiangiogênico anticâncer anticoagulantes antifúngicos antiprotozoários antivirais artemisinina arXiv asma asthma atopia atualização aula aulas auto-arquivamento avastin avermectina bevacizumab biologicals bioRxiv Blogger brain tumor bundler cancer cancerologia pediátrica Carlos Chagas carne vermelha cauterização Ceará CERN child chronic fatigue syndrome ciência ciência brasileira ciências biológicas e da saúde cientistas influentes cirurgia CLI Command Line Tools conselho internacional crime virtual CT scans Curtis Harris darbopoietina dermatite desenvolvedor diabetes dieta disautonomia dislipidemias doença renal doenças cardíacas doenças parasitárias dor DPOC eczema editoras predatórias efeitos adversos eficácia ensino e pesquisa eritropoietina erlotinib ESA escleroterapia estatinas esteróides estilo de vida exercícios F1000Research farmacogenética farmacologia fatores de crescimento fibromialgia Figshare Fisiologia e Medicina fitness flu FMJ Fortaleza fosfoetanolamina fraude acadêmica fraude eletrônica genetics GitHub glioblastoma gliomas Google Books Google mapas gordos green way Harald zur Hausen hemangiomas hemophagocytic lymphohistiocytosis High Sierra homebrew horário imagem immunology imunossupressores imunoterapia infecção urinária inibidores de ECA inibidores tirosina-quinase iniciação científica insulina irracionalismo ivermectina Jeffrey Beall Jekyll journal hijack Lectures lepra leucemia leukemia linfangiomas Mac OS Mac OS X macrophage activation syndrome magrinhas mal-formações March for Science Marcha pela Ciência medicina personalizada meta-análise Milton Santos modelos monoclonais monoclonal antibody mortalidade morte mudança Mulliken neuro-oncologia neuroblastoma neurology ngram viewer Nobel Nobel em Medicina ou Fisiologia novas drogas novos tratamentos obesidade ômega 3 open access open science OpenAIRE osteoporose Osvaldo Cruz package installer pediatria pediatric cancer pediatric tumors pediatrics peer review PeerJ personalized medicine PET/CT pharmacogenetics pharmacological treatment pharmacology plágio política de C&T posters postprints predatory publishers Preprints pressão arterial prevenção progressista projeto de pesquisa propranolol próstata publicação publicação científica publicações publication pubmed Python python 2 python 3 quimioterapia radiation radioterapia rapamycin rbenv recidiva regressão espontânea Regulação médica repository resposta resultados retrospectiva revisão por pares risco Ruby Satoshi Ömura Scholarly Open Access science ScienceNOW seguimento selênio self-archiving sequestro de periódico científico serotonina SIDA sildenafil slides sobrevida sulfa suplementos survival tacerva targeted therapy temozolamida temozolomide terapia alternativa tireóide tratamento tuberculose tumores cerebrais tumores pediátricos vaccine vacina venv via dourada via verde virtualenv virtualenvwrapper vitamina E vitaminas William C. Campbell Xcode Youyou Tu Zenodo

Postagens populares